INT101414

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 27
Total Number 27
Disease Relevance 9.55
Pain Relevance 7.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Phc1) DNA binding (Phc1)
Anatomy Link Frequency
plasma 2
neurons 2
blood 1
nervous system 1
Phc1 (Mus musculus)
Pain Link Frequency Relevance Heat
Clonidine 120 99.98 Very High Very High Very High
anticonvulsant 8 99.60 Very High Very High Very High
imagery 24 99.50 Very High Very High Very High
addiction 64 98.96 Very High Very High Very High
transdermal 12 98.76 Very High Very High Very High
Dopamine 452 98.72 Very High Very High Very High
tolerance 16 98.64 Very High Very High Very High
Locus ceruleus 26 98.16 Very High Very High Very High
Central nervous system 52 98.04 Very High Very High Very High
Morphine 11 96.84 Very High Very High Very High
Disease Link Frequency Relevance Heat
Attention Deficit Hyperactivity Disorder 1237 99.52 Very High Very High Very High
Myocardial Infarction 8 99.50 Very High Very High Very High
Schizotypal Personality Disorder 8 99.12 Very High Very High Very High
Anxiety Disorder 40 98.86 Very High Very High Very High
Sudden Death 24 98.48 Very High Very High Very High
Psychosis 36 97.80 Very High Very High Very High
Hypertrophic Cardiomyopathy 8 97.72 Very High Very High Very High
Manic Depressive Disorder 32 97.28 Very High Very High Very High
Heart Disease 21 96.40 Very High Very High Very High
Depression 52 95.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These findings demonstrate that MPH exposure during the pre-weanling period has long-lasting effects that include enhanced morphine antinociception and tolerance.
Gene_expression (exposure) of MPH associated with antinociception, tolerance and morphine
1) Confidence 0.60 Published 2009 Journal Neuropharmacology Section Abstract Doc Link 19646456 Disease Relevance 0.05 Pain Relevance 1.75
MPH1 and MPH2 were produced through hydrolysis of glycomacropeptide and casein, respectively.
Gene_expression (produced) of MPH1
2) Confidence 0.32 Published 2010 Journal Nutr J Section Body Doc Link PMC2989300 Disease Relevance 0.07 Pain Relevance 0.04
Next to effects on activity and self-regulation, increases in heart rate and blood pressure are characteristic side effects of MPH after single oral and intravenous drug doses as well as after long-time treatment [38, 51, 58].
Gene_expression (effects) of MPH in blood
3) Confidence 0.11 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.13 Pain Relevance 0.60
Imaging studies have shown that MPH produces more efficient PFC function in ADHD patients and healthy controls [36, 53].
Gene_expression (produces) of MPH associated with attention deficit hyperactivity disorder and imagery
4) Confidence 0.11 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.64 Pain Relevance 0.48
Although dopamine levels were not directly measured, the results support the notion that MPH produces biphasic effects via modulation of tonic and phasic dopamine.
Gene_expression (produces) of MPH associated with dopamine
5) Confidence 0.11 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0 Pain Relevance 0.18
At higher MPH doses, the magnitude of the increase is argued to markedly raise both the resting level of extracellular dopamine and the pulsatile dopamine output, thereby causing widespread stimulation of postsynaptic dopamine receptors, overcoming the presynaptic inhibition of further neurotransmitter release, and triggering generalized stimulation of the nervous system (for a review see [42, 43]).


Gene_expression (doses) of MPH in nervous system associated with neurotransmitter, dopamine and dopamine receptor
6) Confidence 0.11 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701285 Disease Relevance 0.10 Pain Relevance 0.62
There were no differences between the IR-MPH (tid) and the OROS-MPH groups with the exception of a smaller increase in pulse in OROS-MPH group that, although statistically significant (p = 0.049), would be of limited clinical significance.
Gene_expression (groups) of MPH
7) Confidence 0.10 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.82 Pain Relevance 0.15
At baseline, there were small statistically significant but not clinically meaningful differences in global assessment of functioning and ratings of anxiety that were slightly worse in the OROS-MPH than in the IR MPH groups (Table 1).
Gene_expression (groups) of MPH associated with anxiety disorder
8) Confidence 0.10 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.19 Pain Relevance 0
There were no differences between the IR-MPH (tid) and the OROS-MPH groups with the exception of a smaller increase in pulse in OROS-MPH group that, although statistically significant (p = 0.049), would be of limited clinical significance.
Gene_expression (group) of MPH
9) Confidence 0.10 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.79 Pain Relevance 0.15
In placebo, IR-MPH (tid) and OROS-MPH subjects the reasons for dropout were: adverse effects (N = 5, N = 14, and N = 9, respectively), lost to follow-up (N = 3, N = 3, and N = 4, respectively), procedural/lack of compliance (N = 6, N = 9 and N = 0, respectively), and lack of effect (N = 4, N = 0, and N = 0, respectively).
Gene_expression (subjects) of MPH
10) Confidence 0.10 Published 2007 Journal BMC Psychiatry Section Body Doc Link PMC2075491 Disease Relevance 0.11 Pain Relevance 0
The ratio of d-MPH and l-MPH plasma concentrations was significantly decreased in the mice treated with aripiprazole compared to the control animals, indicating an overall decrease of CES1 catalytic activity in aripiprazole treated animals.
Gene_expression (plasma) of MPH in plasma
11) Confidence 0.07 Published 2010 Journal Toxicology Section Abstract Doc Link 20097249 Disease Relevance 0 Pain Relevance 0.08
The ratio of d-MPH and l-MPH plasma concentrations was significantly decreased in the mice treated with aripiprazole compared to the control animals, indicating an overall decrease of CES1 catalytic activity in aripiprazole treated animals.
Gene_expression (plasma) of MPH in plasma
12) Confidence 0.07 Published 2010 Journal Toxicology Section Abstract Doc Link 20097249 Disease Relevance 0 Pain Relevance 0.08
CES1 inhibition represents an overlooked and little studied source of variability in MPH disposition, tolerability, and response.
Gene_expression (disposition) of MPH
13) Confidence 0.07 Published 2010 Journal Toxicology Section Abstract Doc Link 20097249 Disease Relevance 0 Pain Relevance 0.06
In 10 patients treated with MPH, single photon emission computed tomography (SPECT) imaging demonstrated that MPH lowered striatal DAT availability in adults with ADHD.52
Gene_expression (treated) of MPH associated with attention deficit hyperactivity disorder and imagery
14) Confidence 0.07 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.62 Pain Relevance 0.31
Cases of sudden cardiac death have been reported when prescribing MPH in combination with clonidine; however, such events are rare when MPH is used as a single agent.
Gene_expression (prescribing) of MPH associated with myocardial infarction and clonidine
15) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 1.27 Pain Relevance 0.13
Short-acting preparations of MPH:
Gene_expression (preparations) of MPH
16) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 0.22 Pain Relevance 0.29
Results indicated no significant benefit of clonidine over MPH as measured by the Connor’s Teachers Abbreviated Symptom Questionnaire.69


Gene_expression (over) of MPH associated with clonidine
17) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2732009 Disease Relevance 1.16 Pain Relevance 0.78
Under the whole cell patch-clamp condition, MPH (30-300 microM) produced an outward current (I(MPH)) with amplitude of 110 +/- 6 pA (n = 17) in LC neurons.
Gene_expression (produced) of MPH in neurons associated with locus ceruleus
18) Confidence 0.04 Published 2002 Journal J. Neurophysiol. Section Abstract Doc Link 11877494 Disease Relevance 0.29 Pain Relevance 0.61
These results suggest that the I(MPH) is produced by activation of inward rectifier K(+) channels in LC neurons.
Gene_expression (produced) of MPH in neurons associated with locus ceruleus
19) Confidence 0.04 Published 2002 Journal J. Neurophysiol. Section Abstract Doc Link 11877494 Disease Relevance 0.12 Pain Relevance 0.29
Pharmacologic action is due to CNS dopamine rise because of dopamine transporter binding.14,20 Side effects are similar to those of MPH products including the well-known addiction potential.


Gene_expression (products) of MPH associated with addiction, dopamine and central nervous system
20) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695228 Disease Relevance 0.09 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox